Table 2.
Survey 1 | Survey 2 | Survey 3 | |||||||
---|---|---|---|---|---|---|---|---|---|
Antibiotic | Proportion of Prescriptions, Number a % | Duration, Days, Median (IQR) | Proportion of Prescriptions, Number a % | Duration, Days, Median (IQR) | Proportion of Prescriptions, Number a % | Duration, Days, Median (IQR) | |||
3GCb | 193/241 | 80.1 | 5.0 (3.0–8.0) | 80/121 | 66.1 | 4.0 (2.0–7.0) | 177/330 | 53.6 | 4.0 (2.0–7.0) |
Ciprofloxacin | 18/241 | 7.5 | 4.0 (3.0–4.0) | 20/121 | 16.5 | 6.0 (5.0–7.0) | 44/330 | 13.3 | 3 (1.75–7.25) |
Amoxicillin | 14/241 | 5.8 | 3.0 (2.0–5.0) | 12/121 | 9.9 | 5.0 (2.5–7.0) | 42/330 | 12.7 | 3.5 (1.0–6.0) |
Metronidazole | 9/241 | 3.7 | 7.0 (5.0–8.0) | 4/121 | 3.3 | 3.0 (2.5–3.5) | 33/330 | 10.0 | 3.0 (2.0–6.0) |
Flucloxacillin | 3/241 | 0.9 | 5.0 (3.0–11.5) | 0 | 0 | - | 5/330 | 1.5 | 6.0 (1.0–15.0) |
Erythromycin | 2/241 | 0.8 | 4.0 (3.0–4.0) | 0 | 0 | - | 1/330 | 0.3 | 1 |
Benzylpenicillin | 1/241 | 0.4 | 6.0 | 1/121 | 0.8 | 1 | 1/330 | 0.3 | 12 |
Co-amoxiclav | 1/241 | 0.4 | 6.0 | 1/120 | 0.8 | 3 | 9/330 | 2.7 | 2.0 (2.0–3.0) |
Doxycycline | 0 | 0 | - | 2/121 | 1.7 | 4.4 (4.25–4.75) | 2/330 | 0.6 | 5 |
Gentamicin | 0 | 0 | - | 1/121 | 0.8 | 1 | 4/330 | 1.2 | 1.5 (0–3.5) |
Co-trimoxazole | 0 | 0 | - | 0 | 0 | - | 12/330 | 3.6 | 4 (2.75–5.25) |
All | 241 | 100 | 4.5 (3.0–7.0) | 120 | 100 | 5.0 (2.0–7.0) | 330 | 100 | 4 (2–6) |
Total costc | US$1907.04 | US$584.78 | US$1404.34 | ||||||
Cost per patientc | US$9.39 | US$5.85 | US$7.02 |
Abbreviations: 3CG, third-generation cephalosporin; IQR, interquartile range.
a The denominator is the number of individual antibiotic prescriptions in each survey, not the number of patients. An individual antibiotic prescription was defined as each prescription written on the patient’s chart. If the antibiotic was switched, this was counted as a second prescription.
bCefotaxime was used in place of ceftriaxone during a period of ceftriaxone shortage in 2017.
c2017 US Dollars.